Modality
Gene Therapy
MOA
MDM2i
Target
TYK2
Pathway
Notch
GAMelanoma
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
~Mar 2018
→ ~Jun 2019
Phase 3
Sep 2019
→ Jan 2029
Phase 3Current
NCT08934250
214 pts·Melanoma
2023-02→2025-06·Active
NCT04113519
1,360 pts·GA
2022-07→2029-01·Recruiting
NCT05959987
289 pts·GA
2019-09→2028-12·Terminated
+1 more trial
1,957 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-06-0910mo agoPh3 Readout· Melanoma
2028-11-162.6y awayPh3 Readout· GA
2028-12-112.7y awayPh3 Readout· GA
2029-01-272.8y awayPh3 Readout· GA
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Termina…
P3
Complet…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2025-06-09 · 10mo ago
Melanoma
Ph3 Readout
2028-11-16 · 2.6y away
GA
Ph3 Readout
2028-12-11 · 2.7y away
GA
Ph3 Readout
2029-01-27 · 2.8y away
GA
RecruitingActiveCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08934250 | Phase 3 | Melanoma | Active | 214 | BodyWt |
| NCT04113519 | Phase 3 | GA | Recruiting | 1360 | Safety |
| NCT05959987 | Phase 3 | GA | Terminated | 289 | Biomarker |
| NCT07648214 | Phase 3 | GA | Completed | 94 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK | |
| COR-9566 | Corcept | Approved | TYK2 |